



## Introduction to LEO Pharma's Open Innovation platform

This is a one-page executive summary highlighting the key points of LEO Pharma Open Innovation. LEO Pharma is a foundation-owned pharmaceutical company focusing on dermatology and skin inflammation and with a well-established product portfolio.

LEO Pharma is interested in exploring new opportunities and ways of working with external research partners. To achieve this LEO Pharma has established an open innovation and collaborative space where unique research tools are made available for external partners.

### What we offer you:

- Free testing of molecules in disease-relevant, cell based in vitro assays
- Description of the assays used and the science behind (see other side of this page)
- Structural confidentiality – your compound's structure does not have to be disclosed
- No binding contracts are signed – Partner can walk away at any time
- No business restrains – focus initially on collaborative creation of scientific data
- Partner owns generated data, LEO Pharma only use to evaluate scientific interest

### What we would like to achieve:

- Identification of new molecules that can be used in hit, lead or late stage drug discovery
- Exploring new pathways and targets by use of pharmacological tool compounds
- Engagement in an open dialogue of business potential based on collaborative science

Please find more information at the web portal: <http://openinnovation.leo-pharma.com>

We are excited to be able to offer the open innovation platform and welcome you to join our mission and explore new ways of collaborations to bring innovative treatments to patients!

On behalf of LEO Pharma Research,

Niclas Nilsson, MSc PhD  
Head of the Open Innovation Program


and

Jakob Felding, PhD  
Director of Skin Research

*Any questions? Please contact: [open.innovation@leo-pharma.com](mailto:open.innovation@leo-pharma.com)*




## The science and R&D tools in LEO Pharma Open Innovation




### Psoriatic inflammation in human keratinocytes

Primary human keratinocytes are stimulated using a psoriasis-specific cytokine cocktail which induce an inflammatory response measured as an increase in IL-8 secretion. Test molecules are tested for ability to inhibit this inflammatory response. General cell viability is also measured.



### Eczematous inflammation in human keratinocytes

Primary human keratinocytes are stimulated using an eczema-specific cytokine cocktail which induce an inflammatory response measured as an increase in CCL5 secretion. Test molecules are tested for ability to inhibit this inflammatory response as well as cell viability.



### Human PBMC release of TNF-alpha

This 'classic' inflammatory assay utilizes primary human PBMC (Peripheral Blood Mononuclear Cells) activated by LPS. The molecules are tested for the ability to inhibit the LPS-induced TNF-alpha release. A secondary viability readout is also provided.

### What's the next step...

Simply fill out the minimal and specific contract in pdf-format, downloadable from the web portal. We will send you vials for compound transfer asking for 200  $\mu$ L of 1-10 mM in DMSO. We look forward to test your molecules for disease-relevant activity and explore science together!

<http://openinnovation.leo-pharma.com>

### LEO Pharma

LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in over 100 countries around the world, we help people manage their skin disease. Founded in 1908 and owned by the LEO Foundation, we have devoted decades of research and development to delivering products and solutions to people with skin diseases. With no external stakeholders we are first and foremost accountable to patients, and we can commit to long-term innovation.

Today we are a fully integrated global healthcare company offering treatments for psoriasis, eczema, actinic keratosis, acne and skin infections.

We want to help more patients, so we are strengthening our portfolio and pipeline through external partnerships and innovation.

In the future, we want to expand our portfolio to include both topical and systemic treatments in a wider range of dermatology indications. Together with our partners, we will strive to be the leading experts in skin.